DOCSLIB.ORG

Efficacy of Rhythmic Auditory Stimulation on Ataxia and Functional Dependence Post- Cerebellar Stroke" (2020)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy of Rhythmic Auditory Stimulation on Ataxia and Functional Dependence Post- Cerebellar Stroke Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale School of Medicine Physician Associate Program Theses School of Medicine 5-22-2020 Efficacy of Rhythmicudit A ory Stimulation on Ataxia and Functional Dependence Post-Cerebellar Stroke Kaitlin Fitzgerald Yale Physician Associate Program, [email protected] Follow this and additional works at: https://elischolar.library.yale.edu/ysmpa_theses Recommended Citation Fitzgerald, Kaitlin, "Efficacy of Rhythmic Auditory Stimulation on Ataxia and Functional Dependence Post- Cerebellar Stroke" (2020). Yale School of Medicine Physician Associate Program Theses. 13. https://elischolar.library.yale.edu/ysmpa_theses/13 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Medicine Physician Associate Program Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. EFFICACY OF RHYTHMIC AUDITORY STIMULATION ON ATAXIA AND FUNCTIONAL DEPENDENCE POST-CEREBELLAR STROKE A Thesis Presented to The Faculty of the School of Medicine Yale University In Candidacy for the degree of Master of Medical Science May 2020 Kaitlin Fitzgerald, PA-SII Dr. Diana Richardson, MD Class of 2020 Assistant Clinical Professor Yale Physician Associate Program. Yale School of Medicine, Neurology i Table of Contents ABSTRACT .............................................................................................................. iv CHAPTER 1: INTRODUCTION ............................................................................. 1 1.1 Ataxia ...........................................................................................................................2 1.2 Cerebellar stroke ..........................................................................................................4 1.3 Motor recovery following stroke ...................................................................................5 1.4 Traditional stroke rehabilitation ...................................................................................5 1.5 Music therapy ..............................................................................................................7 1.6 Music therapy in stroke rehabilitation ..........................................................................8 1.7 Music therapy outside of stroke ....................................................................................9 1.8 Statement of the problem ........................................................................................... 10 1.9 Goals and objectives ................................................................................................... 11 1.10 Hypothesis ............................................................................................................... 11 1.11 Definitions ................................................................................................................ 12 1.12 References ................................................................................................................ 13 CHAPTER 2: LITERATURE REVIEW ................................................................. 24 2.1 Review of Relevant Literature .................................................................................... 25 2.1.1 The functional cerebellum ............................................................................................................ 25 2.1.2 Cerebellar dysfunction .................................................................................................................. 27 2.1.3 Functional impairment and ataxia in chronic cerebellar stroke ....................................................... 29 2.1.4 The challenge of rehabilitation in chronic stroke ........................................................................... 32 2.1.5 Music therapy in stroke rehabilitation ........................................................................................... 33 2.1.6 Music therapy in other movement disorders ................................................................................. 36 2.2 Review of relevant methods ....................................................................................... 42 2.2.1 Study design ................................................................................................................................. 42 2.2.2 Patient Selection ........................................................................................................................... 43 2.2.3 Clinical management ..................................................................................................................... 43 2.2.4 Experimental Condition................................................................................................................ 44 2.2.6 Primary outcomes ......................................................................................................................... 47 2.2.7 Secondary outcomes ..................................................................................................................... 49 2.2.8 Sample size rationale ..................................................................................................................... 49 2.2.9 Estimated recruitment sites ........................................................................................................... 51 2.2.10 Confounding .............................................................................................................................. 51 2.3 Conclusion ................................................................................................................. 51 2.4 References ................................................................................................................. 53 CHAPTER 3: METHODS ...................................................................................... 73 3.1 Study design .............................................................................................................. 74 3.2 Procedures and site selection ..................................................................................... 74 ii 3.3 Study population and sampling .................................................................................. 75 3.4 Subject confidentiality ............................................................................................... 76 3.5 Study variables and measures ..................................................................................... 76 3.6 Methodology considerations ...................................................................................... 77 3.7 Randomization procedure and assignment of intervention ......................................... 79 3.8 Blinding ..................................................................................................................... 79 3.9 Adherence .................................................................................................................. 80 3.10 Monitoring of adverse events .................................................................................... 80 3.11 Data collection ......................................................................................................... 80 3.12 Sample size calculation............................................................................................. 81 3.13 Analysis .................................................................................................................... 81 3.14 Timeline ................................................................................................................... 82 3.16 Resources & Personnel ............................................................................................. 82 3.2 References ................................................................................................................. 84 CHAPTER 4: CONCLUSIONS .............................................................................. 86 4.1 Advantages ................................................................................................................ 87 4.2 Disadvantages ........................................................................................................... 87 APPENDICES ........................................................................................................ 86 Appendix A: Single Session RAS Gait Training Protocol ................................................. 87 Appendix B: RAS Gait Training and Assessment Schedule ............................................. 86 Appendix C: Sample Size Calculation .............................................................................. 86 Appendix D: Letter to Clinical Service Lines ................................................................... 86 Appendix E: CONSORT Diagram of Participant Recruitment and Enrollment .............. 87 Appendix F: Structured Phone Call Screening Interview ................................................. 86 Appendix G: Inclusion and Exclusion Criteria ................................................................ 88 Appendix H: Informed Consent Forms ........................................................................... 86 Appendix I: Scale for the Assessment and Rating of Ataxia
Load more

Recommended publications
  • Multiplex Families with Multiple System Atrophy
    ORIGINAL CONTRIBUTION Multiplex Families With Multiple System Atrophy Kenju Hara, MD, PhD; Yoshio Momose, MD, PhD; Susumu Tokiguchi, MD, PhD; Mitsuteru Shimohata, MD, PhD; Kenshi Terajima, MD, PhD; Osamu Onodera, MD, PhD; Akiyoshi Kakita, MD, PhD; Mitsunori Yamada, MD, PhD; Hitoshi Takahashi, MD, PhD; Motoyuki Hirasawa, MD, PhD; Yoshikuni Mizuno, MD, PhD; Katsuhisa Ogata, MD, PhD; Jun Goto, MD, PhD; Ichiro Kanazawa, MD, PhD; Masatoyo Nishizawa, MD, PhD; Shoji Tsuji, MD, PhD Background: Multiple system atrophy (MSA) has Results: Consanguineous marriage was observed in 1 been considered a sporadic disease, without patterns of of 4 families. Among 8 patients, 1 had definite MSA, 5 inheritance. had probable MSA, and 2 had possible MSA. The most frequent phenotype was MSA with predominant parkin- Objective: To describe the clinical features of 4 multi- sonism, observed in 5 patients. Six patients showed pon- plex families with MSA, including clinical genetic tine atrophy with cross sign or slitlike signal change at aspects. the posterolateral putaminal margin or both on brain mag- netic resonance imaging. Possibilities of hereditary atax- Design: Clinical and genetic study. ias, including SCA1 (ataxin 1, ATXN1), SCA2 (ATXN2), Machado-Joseph disease/SCA3 (ATXN1), SCA6 (ATXN1), Setting: Four departments of neurology in Japan. SCA7 (ATXN7), SCA12 (protein phosphatase 2, regula- tory subunit B, ␤ isoform; PP2R2B), SCA17 (TATA box Patients: Eight patients in 4 families with parkinson- binding protein, TBP) and DRPLA (atrophin 1; ATN1), ism, cerebellar ataxia, and autonomic failure with age at ␣ onset ranging from 58 to 72 years. Two siblings in each were excluded, and no mutations in the -synuclein gene family were affected with these conditions.
    [Show full text]
  • Cerebellar Ataxia
    CEREBELLAR ATAXIA Dr. Waqar Saeed Ziauddin Medical University, Karachi, Pakistan What is Ataxia? ■ Derived from a Greek word, ‘A’ : not, ‘Taxis’ : orderly Ataxia is defined as an inability to maintain normal posture and smoothness of movement. Types of Ataxia ■ Cerebellar Ataxia ■ Sensory Ataxia ■ Vestibular Ataxia Cerebellar Ataxia Cerebrocerebellum Spinocerebellum Vestibulocerebellum Vermis Planning and Equilibrium balance Posture, limb and initiating and posture eye movements movements Limb position, touch and pressure sensation Limb ataxia, Eye movement dysdiadochokinesia, disorders, Truncal and gait Dysmetria dysarthria nystagmus, VOR, ataxia hypotonia postural and gait. Gait ataxia Types of Cerebellar Ataxia • Vascular Acute Ataxia • Medications and toxins • Infectious etiologies • Atypical Infectious agents • Autoimmune disorders • Primary or metastatic tumors Subacute Ataxia • Paraneoplastic cerebellar degeneration • Alcohol abuse and Vitamin deficiencies • Systemic disorders • Autosomal Dominant Chronic • Autosomal recessive Progressive • X linked ataxias • Mitochondrial • Sporadic neurodegenerative diseases Vascular Ataxia ▪ Benedikt Syndrome It is a rare form of posterior circulation stroke of the brain. A lesion within the tegmentum of the midbrain can produce Benedikt Syndrome. Disease is characterized by ipsilateral third nerve palsy with contralateral hemitremor. Superior cerebellar peduncle and/or red nucleus damage in Benedikt Syndrome can further lead in to contralateral cerebellar hemiataxia. ▪ Wallenberg Syndrome In
    [Show full text]
  • Spinocerebellar Ataxia Type 29 Due to Mutations in ITPR1: a Case Series and Review of This Emerging Congenital Ataxia Jessica L
    Zambonin et al. Orphanet Journal of Rare Diseases (2017) 12:121 DOI 10.1186/s13023-017-0672-7 RESEARCH Open Access Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia Jessica L. Zambonin1*, Allison Bellomo2, Hilla Ben-Pazi3, David B. Everman2, Lee M. Frazer2, Michael T. Geraghty4, Amy D. Harper5, Julie R. Jones2, Benjamin Kamien6, Kristin Kernohan1,4, Mary Kay Koenig7, Matthew Lines4, Elizabeth Emma Palmer8,9, Randal Richardson10, Reeval Segel11, Mark Tarnopolsky12, Jason R. Vanstone4, Melissa Gibbons13, Abigail Collins14, Brent L. Fogel15, Care4Rare Canada Consortium, Tracy Dudding-Byth16 and Kym M. Boycott1,4 Abstract Background: Spinocerebellar ataxia type 29 (SCA29) is an autosomal dominant, non-progressive cerebellar ataxia characterized by infantile-onset hypotonia, gross motor delay and cognitive impairment. Affected individuals exhibit cerebellar dysfunction and often have cerebellar atrophy on neuroimaging. Recently, missense mutations in ITPR1 were determined to be responsible. Results: Clinical information on 21 individuals from 15 unrelated families with ITPR1 mutations was retrospectively collected using standardized questionnaires, including 11 previously unreported singletons and 2 new patients from a previously reported family. We describe the genetic, clinical and neuroimaging features of these patients to further characterize the clinical features of this rare condition and assess for any genotype-phenotype correlation for this disorder. Our cohort consisted of 9 males and 12 females, with ages ranging from 28 months to 49 years. Disease course was non-progressive with infantile-onset hypotonia and delays in motor and speech development. Gait ataxia was present in all individuals and 10 (48%) were not ambulating independently between the ages of 3–12 years of age.
    [Show full text]
  • Diagnostic Clues in Multiple System Atrophy
    DO I:10.4274/Tnd.82905 Case Report / Olgu Sunumu Diagnostic Clues in Multiple System Atrophy: A Case Report and Literature Review Multisistem Atrofi Tanısında İpuçları: Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi Mehmet Yücel, Oğuzhan Öz, Hakan Akgün, Semai Bek, Tayfun Kaşıkçı, İlter Uysal, Yaşar Kütükçü, Zeki Odabaşı Gülhane Military Medical Academy, Ankara, Turkey Sum mary Multiple system atrophy (MSA) is an adult-onset, sporadic, progressive neurodegenerative disease. Based on the consensus criteria, patients with MSA are clinically classified into cerebellar (MSA-C) and parkinsonian (MSA-P) subtypes. In addition to major diagnostic criteria including poor response to levodopa, and presence of pyramidal or cerebellar signs (ataxia) or autonomic failure, certain clinical features or ‘‘red flags’’ may raise the clinical suspicion for MSA. In our case report we present a 67-year-old female patient admitted to our hospital due to inability to walk, with poor response to levodopa therapy, whose neurological examination revealed severe Parkinsonism, ataxia and who fulfilled all criteria for MSA, as rarely seen in clinical practice.(Turkish Journal of Neurology 2013; 19:28-30) Key Words: Multiple system atrophy, autonomic failure, diagnostic criteria Özet Multisistem atrofi (MSA) erişkin dönemde başlayan, ilerleyici, nedeni bilinmeyen sporadik nörodejeneratif bir hastalıktır. MSA kabul görmüş tanı kriterlerine göre klinik olarak serebellar (MSA-C) ve parkinsoniyen (MSA-P) alt tiplerine ayrılmaktadır. Düşük levadopa yanıtı, piramidal, serebellar bulguların (ataksi) ya da otonomik bozukluk olması gibi majör tanı kriterlerininin yanında “red flags” olarak isimlendirilen belirgin klinik bulgular ya da uyarı işaretlerinin olması MSA tanısı için klinik şüpheyi oluşturmalıdır. Olgu sunumunda 67 yaşında yürüyememe şikayeti ile polikliniğimize müracaat eden ve levadopa tedavisine düşük yanıt gösteren ciddi parkinsonizm bulguları ile ataksi bulunan kadın hasta MSA tanı kriterlerini tam olarak karşıladığı ve klinik pratikte nadir görüldüğü için sunduk.
    [Show full text]
  • Molecular Diagnostics of Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies
    17_Lupski 3/30/06 1:47 PM Page 243 NeuroMolecular Medicine Copyright © 2006 Humana Press Inc. All rights of any nature whatsoever reserved. ISSN0895-8696/06/08:243–254/$30.00 doi: 10.1385/NMM:8:1:243 REVIEW ARTICLE Molecular Diagnostics of Charcot-Marie-Tooth Disease and Related Peripheral Neuropathies Kinga Szigeti,1 Eva Nelis,2,3 and James R. Lupski*,1,4 1Departments of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; 2Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium; 3Laboratory of Neurogenetics, Institute Born-Borge, University of Antwerp, Antwerpen, Belgium; and 4Pediatrics, Baylor College of Medicine, and Texas Children Hospital, Houston, TX 77030 Received January 10, 2006; Revised January 13, 2006; Accepted January 13, 2006 Abstract DNAdiagnostics plays an important role in the characterization and management of patients manifesting inherited peripheral neuropathies. We describe the clinical integration of molecular diagnostics with medical history, physical examination, and electrophysiological studies. Mole- cular testing can help establish a secure diagnosis, enable genetic counseling regarding recurrence risk, potentially provide prognostic information, and in the near future may be important for the choice of therapies. doi: 10.1385/NMM:8:1:243 Index Entries:Molecular diagnostics; Charcot-Marie-Tooth disease; CMT; hereditary neuropathy with liability to pressure palsies; HNPP; Dejerine-Sottas neuropathy; DSN; congenital hypomyelinating neuropathy; CHN; CMT1A duplication; HNPP deletion. Introduction genetic testing, one needs to be familiar with the diagnostic tests available, choose the appropriate Molecular genetic diagnosis has become an inte- patients for testing, and utilize the diagnostic tools gral part of the evaluation of patients with hered- in a logical fashion to optimize the use of resources.
    [Show full text]
  • A Review on Parkinson's Disease Treatment
    Lee et al. Neuroimmunol Neuroinflammation 2021;8:[Online First] Neuroimmunology DOI: 10.20517/2347-8659.2020.58 and Neuroinflammation Review Open Access A review on Parkinson’s disease treatment Tori K. Lee, Eva L. Yankee Department of Biology, Pacific Union College, Angwin, CA 94508, USA. Correspondence to: Tori K. Lee, Department of Biology, Pacific Union College, 1 Angwin Ave, Angwin, CA 94508, USA. E-mail: [email protected] How to cite this article: Lee TK, Yankee EL. A review on Parkinson’s disease treatment. Neuroimmunol Neuroinflammation 2021;8:[Online First]. http://dx.doi.org/10.20517/2347-8659.2020.58 Received: 1 Oct 2020 First Decision: 1 Dec 2020 Revised: 15 Dec 2020 Accepted: 24 Dec 2020 Available online: 25 Jan 2021 Academic Editors: Athanassios P. Kyritsis, Backil Sung Copy Editor: Monica Wang Production Editor: Jing Yu Abstract Parkinson’s disease (PD) is a neurodegenerative illness and has a common onset between the ages of 55 and 65 years. There is progressive development of both motor and non-motor symptoms, greatly affecting one’s overall quality of life. While there is no cure, various treatments have been developed to help manage the symptoms of PD. Management of PD is a growing field and targets new treatment methods, as well as improvements to old ones. Pharmacological, surgical, and therapeutic treatments have allowed physicians to treat not only the main motor symptoms of PD, but target patient-specific problems as they arise. This review discusses both the established and new possibilities for PD treatment that can provide patient-specific care and mitigate side effects for common treatments.
    [Show full text]
  • Cognitive Impairments in Patients with Congenital Nonprogressive Cerebellar Ataxia
    1/26/2011 Cognitive impairments in patients with… Articles Cognitive impairments in patients with congenital nonprogressive cerebellar ataxia Maja Steinlin, MD, Marianne Styger, LicPhil and Eugen Boltshauser, MD + Author Affiliations Address correspondence and reprint requests to Dr. Maja Steinlin, Division of Neurology, University Children’s Hospital, Inselspital, 3010 Bern, Switzerland; e-mail: [email protected] Abstract Objective: To report neuropsychologic functions and developmental problems of patients with congenital nonprogressive cerebellar ataxia. Background: Growing interest in cerebellar function has prompted closer attention to cognitive impairments in patients with cerebellar damage. Methods: The authors studied 11 patients with nonprogressive congenital ataxia (NPCA) with Wechsler’s intelligence testing, with additional tests of attention, memory, language, visual perception, and frontal functions. Results: Seven of the 11 patients had an IQ of 60 to 92, with marked nonverbal deficits and subnormal to normal verbal performance (group A). Four patients had an IQ of 30 to 49 without pronounced profile asymmetry (group B). Four of the 7 group A patients had decreased alertness and sustained attention, but all had normal selective attention. Tests of frontal functions and memory yielded higher verbal scores than nonverbal scores. There was no deficit on the Aachener Naming Test (similar to the Boston Naming Test), because there were marked difficulties in the majority with visuoconstructive tasks and visual perception. Group B was significantly abnormal in almost all subtests, having a less prominent but similar profile. Conclusion: Patients with NPCA have significant cognitive deficits with an asymmetric profile and better verbal than nonverbal performance. Effects on nonverbal performance of longstanding deficits in visuospatial input during learning, the influence of impaired procedural learning, and asymmetric plasticity of the cerebral hemispheres may contribute to this uneven neuropsychological profile.
    [Show full text]
  • Neurologic Outcomes in Friedreich Ataxia: Study of a Single-Site Cohort E415
    Volume 6, Number 3, June 2020 Neurology.org/NG A peer-reviewed clinical and translational neurology open access journal ARTICLE Neurologic outcomes in Friedreich ataxia: Study of a single-site cohort e415 ARTICLE Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort e440 ARTICLE Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy e428 ARTICLE Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy revisited: Genotype-phenotype correlations of all published cases e434 Academy Officers Neurology® is a registered trademark of the American Academy of Neurology (registration valid in the United States). James C. Stevens, MD, FAAN, President Neurology® Genetics (eISSN 2376-7839) is an open access journal published Orly Avitzur, MD, MBA, FAAN, President Elect online for the American Academy of Neurology, 201 Chicago Avenue, Ann H. Tilton, MD, FAAN, Vice President Minneapolis, MN 55415, by Wolters Kluwer Health, Inc. at 14700 Citicorp Drive, Bldg. 3, Hagerstown, MD 21742. Business offices are located at Two Carlayne E. Jackson, MD, FAAN, Secretary Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Production offices are located at 351 West Camden Street, Baltimore, MD 21201-2436. Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, Treasurer © 2020 American Academy of Neurology. Ralph L. Sacco, MD, MS, FAAN, Past President Neurology® Genetics is an official journal of the American Academy of Neurology. Journal website: Neurology.org/ng, AAN website: AAN.com CEO, American Academy of Neurology Copyright and Permission Information: Please go to the journal website (www.neurology.org/ng) and click the Permissions tab for the relevant Mary E.
    [Show full text]
  • Ataxia Digest
    Ataxia Digest 2015 Vol. 2 News from the Johns Hopkins Ataxia Center 2016 What is Ataxia? Ataxia is typically defined as the presence of Regardless of the type of ataxia a person may have, it abnormal, uncoordinated movements. This term is is important for all individuals with ataxia to seek proper most often, but not always, used to describe a medical attention. For the vast majority of ataxias, a neurological symptom caused by dysfunction of the treatment or cure for the disease is not yet available, so cerebellum. The cerebellum is responsible for many the focus is on identifying symptoms related to or motor functions, including the coordination of caused by the ataxia. By identifying the symptoms of voluntary movements and the maintenance of balance ataxia it becomes possible to treat those symptoms and posture. through medication, physical therapy, exercise, other therapies and sometimes medications. Those with cerebellar ataxia often have an “ataxic” gait, which is walking The Johns Hopkins Ataxia Center has a that appears unsteady, uncoordinated multidisciplinary clinical team that is dedicated to and staggered. Other activities that helping those affected by ataxia. The center has trained require fine motor control like writing, specialist ranging from neurologists, nurses, reading, picking up objects, speaking rehabilitation specialists, genetic counselors, and many clearly and swallowing may be others. This edition of the Ataxia Digest will provide abnormal. Symptoms vary depending you with information on living with ataxia and the on the cause of the ataxia and are multidisciplinary center at Johns Hopkins. specific to each person. Letter from the Director Welcome to the second edition of the Ataxia Digest.
    [Show full text]
  • Movement Disorders in the Elderly
    MOVEMENT DISORDERS IN THE ELDERLY Eugene C. Lai, M.D., Ph.D. Michael E. DeBakey VA Medical Center Baylor College of Medicine Houston, Texas MOVEMENT DISORDERS Neurologic dysfunctions in which there is either a paucity of voluntary and automatic movements (HYPOKINESIA) or an excess of movement (HYPERKINESIA) or uncontrolled movements (DYSKINESIA) typically unassociated with weakness or spasticity HYPOKINESIAS • Parkinson‟s disease • Secondary Parkinsonism • Parkinson‟s plus syndromes HYPERKINESIAS • Akathisia • Hemifacial spasm • Athetosis • Myoclonus • Ballism • Restless leg syndrome • Chorea • Tics • Dystonia • Tremor COMMON MOVEMENT DISORDERS IN THE ELDERLY • Parkinsonism • Tremor • Gait disorder • Restless leg syndrome • Drug-induced syndrome PARKINSONISM • Parkinson‟s disease • Secondary parkinsonism • Drug-induced parkinsonism • Vascular parkinsonism • Parkinson‟s plus syndromes • Multiple system atrophy • Progressive supranuclear palsy PARKINSON’S DISEASE PARKINSON’S DISEASE Classical Clinical Features • Resting Tremor • Cogwheel Rigidity • Bradykinesia • Postural Instability PARKINSON’S DISEASE Associated Clinical Features • Micrographia • Hypophonia • Hypomimia • Shuffling gait / festination • Drooling • Dysphagia NON-MOTOR COMPLICATIONS IN PARKINSON’S DISEASE • Sleep disturbances • Autonomic dysfunctions • Sensory phenomena • Neuropsychiatric manifestations • Cognitive impairment PARKINSON’S DISEASE General Considerations • The second most common progressive neurodegenerative disorder • The most common neurodegenerative movement
    [Show full text]
  • Children with Ataxia in Conductive Education
    Central Journal of Neurological Disorders & Stroke Short Communication *Corresponding author Erzsébet Balogh, International Pető Association, András Pető College, Gizella út 1. 1143 Budapest, Hungary, Tel: Children with Ataxia in Conductive 003613837255; Email: [email protected] Submitted: 16 September 2020 Education Accepted: 29 September 2020 Published: 30 September 2020 1 2 Erzsébet Balogh * and Éva Feketéné Szabó ISSN: 2334-2307 1International Pető Association, András Pető College, Hungary Copyright 2 András Pető College, Semmelweis University, Hungary © 2020 Balogh E, et al. OPEN ACCESS Abstract Impaired coordination caused by cerebral, cerebellar or spinal impairment, with hypoxic or Keywords genetic causes, answer to the Pető’s conductive education quite fair. It might mean the most favorable • Pető method facilitation for developmental processes and by the so called structural cerebellar reserve or by • Conductive education extra-cerebellar parts of the brain. • Ataxia ABBREVIATIONS CP: Cerebral Palsy; CE: Conductive Education induced abnormal coordination test, become increasingly INTRODUCTION successful with repeated new trials – even in a few minutes. Some elements of classical neurological tests for coordination adapted An accumulation of children with ataxia can be observed in to age can be used extremely advantageously in rehabilitation, conductive educational services worldwide. including conductive education (CE), e.g. imitated play – finger MATERIALS AND METHODS movements on imaginary piano keys, rhythmic, bilateral synchronous or alternating movement series. These are applied facilitationalso in Pető’s tool CE in which CE is usescalled holistic, rhythmical pedagogical intention, tools intention for the global upbringing of infants and children [5,6]. The most powerful Based on the files of previously assessed children with ataxia will be create soon special conductive educational groups.
    [Show full text]
  • Pseudoparkinsonism: a Review of a Common Nonparkinsonian Hypokinetic Movement Disorder
    Vol.2, No.4, 108-112 (2013) Advances in Parkinson’s Disease http://dx.doi.org/10.4236/apd.2013.24020 Pseudoparkinsonism: A review of a common nonparkinsonian hypokinetic movement disorder Roger Kurlan*, Marcie L. Rabin Atlantic Neuroscience Institute, Overlook Medical Center, Summit, USA; *Corresponding Author: [email protected] Received 16 September 2013; revised 16 October 2013; accepted 24 October 2013 Copyright © 2013 Roger Kurlan, Marcie L. Rabin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT [2-4]. Over time, clinicians learned that a variety of entities This article reviews the syndrome pseudopark- besides neuroleptic drugs can similarly cause a clinical insonism, a movement disorder described in the picture resembling that of PD. The notion that a parkin- literature that resembles parkinsonism but dif- sonian syndrome could be caused by cerebrovascular fers qualitatively. Patients with this disorder disease became popularized in the 1980’s and 1990’s. have apraxic slowness, paratonic rigidity, frontal Some publications referred to the condition as “vascular gait disorder and elements of akinesia that, pseudoparkinsonism” [5,6], similar to the term used for taken together, may be mistaken for true park- neuroleptic drugs. Other articles, in contrast, used the insonism. Pseudoparkinsonism appears to be term “vascular parkinsonism” to describe features with a common and is most often due to Alzheimer’s vascular etiology that are reminiscent of, but distinct disease or vascular dementia. It seems that pa- from, those found in PD.
    [Show full text]